What is the price target for ABL stock?
35 analysts have analysed ABL.DE and the average price target is 115.79 EUR. This implies a price increase of 35.05% is expected in the next year compared to the current price of 85.74.
FRA:ABL • US0028241000
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ABBOTT LABORATORIES (ABL.DE).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2021-07-23 | Raymond James | Maintains | Outperform |
| 2021-07-23 | Credit Suisse | Maintains | Outperform |
| 2021-07-23 | Morgan Stanley | Maintains | Overweight |
| 2021-07-20 | SVB Leerink | Maintains | Market Perform |
| 2021-07-12 | Wells Fargo | Maintains | Overweight |
| 2021-06-02 | BTIG | Maintains | Buy |
| 2021-06-02 | Barclays | Maintains | Overweight |
| 2021-06-02 | Wells Fargo | Maintains | Overweight |
| 2021-06-02 | Raymond James | Maintains | Outperform |
| 2021-06-02 | Credit Suisse | Maintains | Outperform |
| 2021-06-02 | Morgan Stanley | Maintains | Overweight |
| 2021-06-02 | Citigroup | Maintains | Buy |
| 2021-05-25 | Barclays | Initiate | Overweight |
| 2021-04-21 | Morgan Stanley | Maintains | Overweight |
| 2021-04-15 | Atlantic Equities | Initiate | Neutral |
| 2021-03-11 | Raymond James | Maintains | Outperform |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 40.109B -8.12% | 41.95B 4.59% | 44.328B 5.67% | 48.804B 10.10% | 52.633B 7.85% | 56.232B 6.84% | 59.182B 5.25% | 63.47B 7.25% | 67.627B 6.55% | 72.345B 6.98% | 77.491B 7.11% | |
| EBITDA YoY % growth | 9.965B -16.78% | 10.211B 2.47% | 11.443B 12.07% | 13.184B 15.21% | 14.453B 9.63% | 15.61B 8.01% | 16.232B 3.98% | 19.36B 19.27% | N/A | N/A | N/A | |
| EBIT YoY % growth | 6.722B -22.80% | 6.993B 4.03% | 8.327B 19.08% | 11.467B 37.71% | 12.503B 9.03% | 13.63B 9.01% | 15.554B 14.12% | 17.187B 10.50% | N/A | N/A | N/A | |
| Operating Margin | 16.76% | 16.67% | 18.78% | 23.50% | 23.76% | 24.24% | 26.28% | 27.08% | N/A | N/A | N/A | |
| EPS YoY % growth | 4.44 -16.85% | 4.67 5.18% | 5.15 10.28% | 5.70 10.72% | 6.28 10.19% | 6.92 10.07% | 7.43 7.37% | 8.44 13.67% | 9.19 8.89% | 10.08 9.67% | 11.06 9.72% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 1.16 6.26% | 1.39 10.13% | 1.47 13.09% | 1.68 12.08% | 1.38 18.97% | 1.55 11.37% | 1.62 10.22% | 1.73 3.08% | 1.57 13.61% | 1.74 12.42% | 1.79 10.33% | 1.87 7.83% |
| Revenue Q2Q % growth | 11.101B 7.17% | 12.168B 9.21% | 12.548B 10.37% | 12.969B 13.18% | 11.965B 7.78% | 12.892B 5.95% | 13.278B 5.82% | 13.694B 5.59% | 12.825B 7.19% | 13.942B 8.14% | 14.397B 8.43% | 14.845B 8.41% |
| EBITDA Q2Q % growth | 2.679B 7.89% | 3.214B -12.07% | 3.405B -24.37% | 3.807B -30.07% | 3.219B 20.16% | 3.536B 10.02% | 3.709B 8.93% | 3.904B 2.55% | 3.628B 12.71% | 3.949B 11.68% | 4.126B 11.24% | 4.247B 8.79% |
| EBIT Q2Q % growth | 2.279B 31.96% | 2.799B 31.90% | 2.971B 36.41% | 3.397B 45.92% | 2.701B 18.52% | 3.037B 8.50% | 3.222B 8.45% | 3.463B 1.94% | 3.206B 18.70% | 3.513B 15.67% | 3.671B 13.94% | 3.8B 9.73% |
All data in USD
35 analysts have analysed ABL.DE and the average price target is 115.79 EUR. This implies a price increase of 35.05% is expected in the next year compared to the current price of 85.74.
ABBOTT LABORATORIES (ABL.DE) will report earnings on 2026-04-14, before the market open.
The consensus EPS estimate for the next earnings of ABBOTT LABORATORIES (ABL.DE) is 1.16 EUR and the consensus revenue estimate is 11.10B EUR.
The consensus rating for ABBOTT LABORATORIES (ABL.DE) is 80.5714 / 100 . This indicates that analysts generally have a positive outlook on the stock.